Quest liver fibrosis panel. Get know how much does lab test cost. The Enhanced Liver Fibrosis (ELF) Score is a noninvasive test that indicates whether a patient with NASH and advanced fibrosis has a higher or lower risk of disease progression to cirrhosis (for those with F3 fibrosis) or other liver-related clinical events (for those with F3 or F4 fibrosis) within 1 to 4 years. Transfer 2 mL serum to an ARUP Standard Transport Tube. Clinical Significance: The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), hepatitis B, or hepatitis C. High rates of obesity, insulin resistance, and metabolic syndrome have led to an increase in metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD). Because The Enhanced Liver Fibrosis (ELF™) blood test is a simple, accurate, non-invasive test that provides a simple, unitless numeric score that is generated via an algorithm for use in advanced liver fibrosis. ”1 Liver Fibrosis, Hepatic Function Panel with Fibrosis-4 (FIB-4) Index - The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). Liver Fibrosis, FibroTest-ActiTest Panel (Quest). Liver Fibrosis, Hepatic Function Panel with Fibrosis-4 (FIB-4) Index - The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). Liver Fibrosis, FibroTest-ActiTest Panel Test Code LAB6081 Quest Code 92688 Alias/See Also Hepatitis C Liver Status Biomarker, Liver Fibrosis Status Clinical Significance Liver Fibrosis, FibroTest-ActiTest Panel - FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease that is strongly related to insulin resistance and metabolic syndrome, and it has become the most common liver disorder in developed countries. 30 or higher, adding an additional charge. It is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-hepatitis (NASH) to 2022 MASLD guideline recommendations for blood testing and referral3 According to recommendations for blood testing and referral developed by AACE and cosponsored by AASLD, patients in the high-risk groups with indeterminate or high FIB-4 index should be considered for further assessment, such as with the Enhanced Liver Fibrosis (ELF™) Score. This test will replace test ID FHFIB Hepatitis C Virus FibroSURE, referred to LabCorp Burlington effective September 30, 2015. Abstract Liver fibrosis reflects sustained liver injury often from multiple, simultaneous factors. Fibrosis occurs when the liver tries to repair itself after injury, creating scar tissue. The Enhanced Liver Fibrosis (ELF™) Score is a simple blood test based on three analytes which directly contribute to liver fibrosis. Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. Reflex tests are performed at an additional charge. Hepatic (liver) function can be measured in terms of serum enzyme activity such as alkaline phosphatase, transaminases, lactic dehydrogenase and serum concentrations of proteins, bilirubin, ammonia, clotting factors and lipids. Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of adults in developed countries. This can progress to metabolic dysfunction-associated steatohepatitis (MASH), putting these patients at risk for cardiovascular disease and end-stage liver disease. Centrifuge, separate serum from cells within 15 - 30 minutes and send 3. FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score - This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel Alternate Name: Liver_Fibrosis-4_Inx_QD SAL Code: Hepatic Function Panel - This panel may be helpful in assessing liver injury, diagnosing liver diseases, and monitoring treatment of liver diseases and adverse effects of hepatotoxic drugs [1]. This is the first FIB-4 index is calculated first; if FIB-4 index value is between 0 and 1. It has not been cleared or approved by FDA. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine . { { metaDesc }} Sorry, we are experiencing an issue with this website. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine Mar 28, 2022 · Clinical Significance: The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), hepatitis B, or hepatitis C. Hepatic Function Panel with FIB-4 Index with Reflex to ELF Score - This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. Interpretations: Quantitative results of 6 biochemical tests are analyzed using a computational algorithm to provide a quantitative surrogate marker (0. FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas Jan 6, 2026 · Summary Steatosis, or fatty liver disease, results from excess fat accumulation in the liver and can progress to fibrosis, a critical predictor of morbidity and mortality in chronic liver diseases like hepatitis B, C, and MASLD. NAFLD embraces the full pathological Sep 22, 2023 · The Enhanced Liver Fibrosis (ELF) test is indicated “as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH), to assess the likelihood of progression to cirrhosis and liver-related clinical events. This test panel assesses both FibroTest and ActiTest scores to detect the presence of liver fibrosis (scarring) and inflammation. If you need assistance in the meantime, please LIVER FIBROSIS, FIBROSIS-4 (FIB-4) INDEX PANEL Test Code LAB3968 Quest Code 30555 CPT Codes 84450, 84460, 85049 Includes Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT) Platelet Count FIB 4 Index Test Summary FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. 1 The FIB-4 Index can A noninvasive approach to assess risk of advanced liver disease Liver disease progression can lead to the development of fibrosis, cirrhosis, and other complications. No doctor’s order needed – simply purchase, access your testing at a nearby location, and get fast results. The ELF score is not for use in the diagnosis of NASH, the staging of fibrosis, the serial monitoring of disease progression, or the monitoring of effects of therapeutic products. Detect and monitor non-alcoholic fatty liver disease (NAFLD), which could lead to liver fibrosis or cirrhosis. Clinical Significance Comprehensive Metabolic Panel with Fibrosis-4 (FIB-4) Index - The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). Whilst the presence of mild fibrosis on biopsy can be a reassuring finding, the identification of advanced fibrosis is critical to the management of patients with chronic liver disease. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 { { metaDesc }} Sorry, we encountered an error in the application. The error below has been logged and our team is working diligently to correct it. • To assess the risk of NAFLD with liver fibrosis, use liver fibrosis prediction calculations. Nov 6, 2024 · The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). CPT coding is the sole responsibility of the billing party. e. Use: Screening patients suspected to be at risk for liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas Jan 26, 2022 · The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. The Fibrosis-4 (FIB-4) Index for Liver Fibrosis is a non-invasive scoring system based on several laboratory tests that help to estimate the amount of scarring in the liver. The issue will be corrected as soon as possible. Liver Fibrosis Panel (HepaScore) Test ID:99981231160000-0800 FLFP , will become obsolete due to reagent issues. FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score (Quest). (Min: 1. Liver Fibrosis, FibroTest-ActiTest Panel - FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. Quest has listed the ALTERNATIVE TEST: FHFIB – Hepatitis C Virus (HCV) FibroSURE METHODOLOGY: Immunologic, Colorimetric, Kinetic – colorimetric, Nephelometry The FIB-4 panel is also offered as the FIB-4 Index Panel With Reflex to Enhanced Liver Fibrosis (ELF) Score (test code 12734), with reflex testing performed at an additional charge with an additional CPT code. No doctor's visit is required - simply purchase, and access testing at a nearby location. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. ||Separate from cells ASAP or within 2 hours of collection. Although liver biopsy remains the gold standard for diagnosing fibrosis, various serum-based non-invasive tests have been proposed as alternatives, including the The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. Please try again The cause of these discordances could be due to a flaw of the Test or to a flaw in the biopsy: i. Quest Diagnostics offers the Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel (test code 30555), which includes tests for AST, ALT, and platelet count, plus calculation of the FIB-4 index. Currently, the ELF Test is exclusively available through collaborations with Labcorp (NYSE: LH) and Quest Diagnostics (NYSE: DGX), providing access (with a physician’s order) across the country. According to recommendations for blood testing and referral developed by AACE and cosponsored by AASLD, the FIB-4 index is the preferred noninvasive initial test to assess the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) with liver fibrosis. Buy your own liver function panel test online with Quest. NAFLD fibrosis score (NFS) is a blood test that calculates the probability of advanced liver fibrosis based on AST, ALT, albumin, age, body mass index (BMI), platelet count, and presence of impaired fasting glucose (IFG) or diabetes. Progressive liver fibrosis is associated with increased risk of cirrhosis and hepatocellular carcinoma (HCC). Alanine Aminotransferase (ALT), Alpha-2-Macroglobulin, Apolipoprotein A1, Total Bilirubin, Gamma Glutamyl Transferase (GGT), Haptoglobin, Fibrosis Score, and Necroinflammat Act Score. The Liver Fibrosis, FibroTest-ActiTest Panel is a non-invasive way to evaluate liver health, specifically designed for individuals with Hepatitis C or B. 3 Announcements FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. Nov 6, 2024 · Comprehensive Metabolic Panel: Albumin, Albumin/Globulin Ratio (calculated), Alkaline Phosphatase, ALT, AST, BUN/Creatinine Ratio (calculated), Calcium, Carbon Dioxide, Chloride, Creatinine with GFR Estimated, Globulin (calculated), Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, Urea Nitrogen Platelet Count FIB 4 Index If FIB-4 Index is ≥1. 0-1. • Consider persons belonging to the “high risk” group who have an indeterminate or high FIB-4 score for further workup with an ELF test. 3 Clinical Significance Enhanced Liver Fibrosis (ELF) Score - The Enhanced Liver Fibrosis (ELF) score predicts progression to cirrhosis and liver-related events in patients with advanced fibrosis due to NASH. 29, testing is reflexed to NASH FibroSure® Plus at an additional cost. This marker is recommended by the American Association of Clinical Endocrinology. NASH FibroSure® Plus test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Test ID: FLFFT EXPLANATION: The following new orderable, referred to Quest Diagnostic Nichols Institute, San Juan Capistrano, is available immediately. The FIB-4 panel is also offered as the FIB-4 Index Panel With Reflex to Enhanced Liver Fibrosis (ELF) Score (test code 12734), with reflex testing performed at an additional charge with an additional CPT code. If the FIB-4 index is ≥1. Nov 7, 2025 · Many labs, such as Quest Diagnostics, offer a FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score. 30, then Enhanced Liver Fibrosis (ELF Order your own liver and kidney function tests online with Quest®. 30, the ELF score is performed. We would like to show you a description here but the site won’t allow us. While convenient, this setup automatically triggers the ELF test if your fib 4 score is 1. 7–10 ELF is included as a Labcorp test details for Liver Fibrosis Risk Profile With Hepatic Function Panel, Complete Blood Count (CBC) With Differential, FIB-4, and APRI The FIB-4 panel is also offered as the FIB-4 Index Panel With Reflex to Enhanced Liver Fibrosis (ELF) Score (test code 12734), with reflex testing performed at an additional charge with an additional CPT code. Feb 23, 2026 · Health Lab << Back To Search Results Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel - The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). Direct access testing with or without insurance. That’s why the American Association for the Study of Liver Diseases recommends the FIB-4 Index as a noninvasive approach to identify patients with a high likelihood of advanced fibrosis. The ELF score predicts progression to cirrhosis and liver-related events in patients with advanced fibrosis due to NASH. It is also not recommended in patients with Gilbert disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra- hepatic cholestasis. 5 mL serum in a screw capped plastic vial. HepaScore is an index derived from serum markers (A2-Macroglobulin, Total Bilirubin, Gamma Glutamyl-transferase (GGT) and Hyaluronic Acid (HA) and demographic rick factors (age and sex) which predicts probability of liver fibrosis. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine A noninvasive approach to assess risk of advanced liver disease Liver disease progression can lead to the development of fibrosis, cirrhosis, and other complications. NAFLD Fibrosis Score - The NAFLD fibrosis score is a simple noninvasive approach to identify patients that may have significant liver fibrosis and who therefore might benefit from additional studies such as elastography or liver biopsy. Order Other-Flexitest to Quest. The ELF LIVER FIBROSIS, FIBROSIS-4 (FIB-4) INDEX PANEL Test Code LAB3968 Quest Code 30555 CPT Codes 84450, 84460, 85049 Includes Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT) Platelet Count FIB 4 Index FIB-4 Index Panel with Reflex to Enhanced Liver Fibrosis (ELF) Score - This reflex provides a cost-effective, medically justified, and guideline supported approach to evaluating a patient at risk of NAFLD with liver fibrosis. FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. Liver disease progression can lead to the development of fibrosis, cirrhosis, and other complications. This necessity has lead to a reliance on liver biopsy which itself is an imperfect test and poorly accepted by Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel Alternate Name: Liver_Fibrosis-4_Inx_QD SAL Code: Clinical Significance: The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), hepatitis B, or hepatitis C. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). FibroTest is interpretable for chronic hepatitis B and C, alcoholic and non-alcoholic steatosis. 2 mL) Lavender (EDTA) or Pink (K2EDTA) for platelet count AND Serum Separator Tube (SST). AST to Platelet Ratio Index (APRI) is reported to be a simple, noninvasive, and readily available laboratory test index that can stratify patients with HCV and Non-Alcoholic Fatty Liver Disease (NAFLD) who are at high or low risk for significant fibrosis and cirrhosis with high degree of accurancy. The preferred noninvasive initial test is the FIB-4. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine The FibroTest-ActiTest panel is a specialized blood test that evaluates the amount of fibrosis (scarring) and inflammatory activity in the liver. Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel - The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). FIB-4 Index FIB-4 Index What it measures: fibrosis Who should take it: anyone concerned about their liver Where to get it: primary care provider, online calculator The FIB-4 Index is a blood-based diagnostic test that looks at underlying fibrosis that can be used as a measure to help determine NAFLD/NASH status. 29, testing stops; if FIB-4 index value is greater than 1. Oct 11, 2023 · FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. 0) for liver fibrosis (METAVIR F0-F4) and for necroinflammatory activity (METAVIR A0-A3). Over time, too much scar tissue disrupts normal liver function, leading to conditions such as cirrhosis (severe scarring), liver failure, or liver cancer. NAFLD represents a wide spectrum of liver pathology and ranges from benign, fatty liver or steatosis to non-alcoholic steatohepatitis (NASH), which is the cause of liver fibrosis. Any Profile/panel component may be ordered separately. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine Clinical Significance Comprehensive Metabolic Panel with Fibrosis-4 (FIB-4) Index - The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4). a liver biopsy has a 33% variability rate for one fibrosis stage. For additional testing options that include the FIB-4 index, consult the Quest online Test Directory. FIB-4 index is reported to FIB-4 index is reported to be a simple, accurate, non-invasive, and readily available laboratory test index that can help in evaluation of patients with HCV and Non-Alcoholic Fatty Liver Disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), for the presence of liver fibrosis indication for liver biopsy Only intended for use in patients with non-alcoholic liver disease (NAFLD); results may be inaccurate in patients with other etiologies of liver disease. Please direct any questions regarding coding to the payor being billed. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and Alanine Aminotransferase (ALT), Alpha-2-Macroglobulin, Apolipoprotein A1, Total Bilirubin, Gamma Glutamyl Transferase (GGT), Haptoglobin, Fibrosis Score, and Necroinflammat Act Score. The ELF Test is a simple, effective blood test with proven patient outcomes data to assess prognosis in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH), a type of non-alcoholic fatty liver disease (NAFLD) characterized by inflammation of the liver. Serum should be separated from the cells as soon as possible after visible clot formation (usually 15-30 minutes after collection). ActiTest is interpretable for chronic hepatitis B and C. saozy zaret whp tciypmh djd xdda odcsvn hwcugpq gihy fgkfd